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BRIEF COMMUNICATION
The neuroprotective agent CNTF decreases neuronal
metabolites in the rat striatum: an in vivo multimodal
magnetic resonance imaging study
Maria-Angeles Carrillo-de Sauvage1,2, Julien Flament1,3, Yann Bramoulle1,2, Lucile Ben Haim1,2, Martine Guillermier1,2,
Aurélie Berniard1,2, Gwennaëlle Aurégan1,2, Diane Houitte1,2, Emmanuel Brouillet1,2, Gilles Bonvento1,2, Philippe Hantraye1,2,3,
Julien Valette1,2 and Carole Escartin1,2
Ciliary neurotrophic factor (CNTF) is neuroprotective against multiple pathologic conditions including metabolic impairment,
but the mechanisms are still unclear. To delineate CNTF effects on brain energy homeostasis, we performed a multimodal imaging
study, combining in vivo proton magnetic resonance spectroscopy, high-performance liquid chromatography analysis,
and in situ glutamate imaging by chemical exchange saturation transfer. Unexpectedly, we found that CNTF expression
through lentiviral gene transfer in the rat striatum significantly decreased the levels of neuronal metabolites (N-acetyl-aspartate,
N-acetyl-aspartyl-glutamate, and glutamate). This preclinical study shows that CNTF remodels brain metabolism, and suggests that
decreased levels of neuronal metabolites may occur in the absence of neuronal dysfunction.
Journal of Cerebral Blood Flow & Metabolism (2015) 35, 917–921; doi:10.1038/jcbfm.2015.48; published online 1 April 2015
Keywords: brain imaging; glutamate; magnetic resonance; N-acetyl-aspartate; reactive astrocytes; striatal metabolism
INTRODUCTION
The cytokine ciliary neurotrophic factor (CNTF) exhibits well-established
neuroprotective effects against a large variety of pathologic conditions,
including excitotoxicity and metabolic impairment.1,2 It has been
tested in clinical trials for Huntington’s disease,3 amyotrophic lateral
sclerosis,4 and diseases of the retina.5 However, the mechanisms
involved in CNTF neuroprotection remain largely uncharacterized.
Ciliary neurotrophic factor is known to directly activate catabolic
pathways in peripheral organs such as the liver, muscle, and
adipose tissues, and to regulate food intake and energy expendi-
ture in the hypothalamus.6 Besides these metabolic effects, CNTF is
a potent activator of astrocytes. We previously reported that
astrocyte activation by CNTF alters their metabolic profile, leading
to protective effects on neurons exposed to glycolytic inhibition.7
Here, we aimed to further delineate CNTF metabolic effects on the
intact brain. We performed a multimodal imaging study combining
proton magnetic resonance spectroscopy (1H-MRS), high-perfor-
mance liquid chromatography (HPLC) analysis and brain mapping
of glutamate (Glu) with Chemical Exchange Saturation Transfer
(gluCEST) on rats injected with a lentiviral vector encoding CNTF.
MATERIALS AND METHODS
Injection of Lentiviral Vectors
We used self-inactivated lentiviral vectors that encode either the human
CNTF gene (‘lenti-CNTF’) or the β-galactosidase gene (‘lenti-LacZ’).8
Two-month-old male Sprague Dawley rats (Charles River,
France) were injected with lentiviral vectors as described
previously,9 and analyzed between 1.5 and 3 months after
injection (CNTF effects being stable for at least 6 months8). To
avoid bias associated with lateralization, both combinations of
injections (lenti-LacZ in the left striatum and lenti-CNTF in the
right striatum, or the opposite) were performed.
Housing and experiments were performed in strict accordance
with the European Community regulations (Directive 2010-63/EEC)
and French regulations (Code Rural R214/87-130). Experimental
procedures were approved by a local ethics committee registered by
the French Research Ministry (committee #44, approval #10-057).
Proton Magnetic Resonance Spectroscopy
Proton magnetic resonance spectroscopy (1H-MRS) experiments
were performed on a horizontal 7 T Agilent scanner (Palo Alto, CA,
USA). We used a volume coil for radiofrequency transmission and
a quadrature surface coil for reception.
T2-weighted images were acquired with a 2D fast spin-echo
sequence, and were then used to position two voxels of
4 × 3.4 × 3mm3 in each striatum for 1H-MRS analysis (Figure 1B).
Excellent shimming (9 to 11 Hz) was achieved in these voxels. A
LASER (Localization by Adiabatic Selective Refocusing) sequence
with echo time/repetition time = 25/5,000 ms was used for 1H-MRS
acquisition (384 repetitions for metabolite spectrum). Pulse
bandwidth of the hyperbolic secant pulses in LASER was equal
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to 10 kHz, ensuring less than 6% chemical shift localization artifact
over the spectral range of the metabolites of interest (2 to 4 ppm).
Metabolite concentrations were quantified with LCModel.10
A macromolecule spectrum was acquired by metabolite nulling
and included in LCModel basis set. Seven metabolites were
reliably quantified (Cramér-Rao lower bounds ⩽ 5%). Meta-
bolite concentrations were normalized to total creatine, set at
8 mmol/L.
Figure 1. Ciliary neurotrophic factor (CNTF) remodels striatal metabolite concentrations as measured by proton magnetic resonance
spectroscopy (1H-MRS). (A) Representative images of immunostaining for vimentin, NeuN, and ED1/CD68. Vimentin is strongly induced in the
lenti-CNTF injected striatum (right), but not in the lenti-LacZ striatum (left). At higher magnification, multiple reactive astrocytes are observed.
There is no difference in the density or the morphology of neuronal cell bodies between the two striata. There is no positive staining for ED1/
CD68, a selective marker of reactive microglia. Scale bar: 1 mm (large panels), 50 μm (small panels). (B) Representative in vivo 1H-MRS spectra
obtained from the two striata, 2 months after lentiviral injection. Analysis by LCModel allows spectra decomposition into (1) neuronal
metabolites (total NAA (tNAA=N-Acetyl-Aspartate (NAA)+ N-Acetyl-Aspartyl-Glutamate (NAAG)) and Glutamate (Glu)); (2) glial metabolites
(Inositol (Ins), total Choline (tCho) and Glutamine (Gln)) (3) other metabolites (Taurine (Tau), total creatine (tCr), and macromolecules (MM)).
Inset, representative T2-weighted image showing the position of the voxel (total volume= 40.8 μL). There is no visible difference in T2 contrast
between striata. (C) Metabolite concentrations measured in both voxels. Green lines correspond to rats injected with lenti-LacZ in the left
striatum and lenti-CNTF in the right striatum; red lines correspond to rats injected with lenti-CNTF in the left striatum and lenti-LacZ in the
right striatum. N= 9; **Po0.01, ***Po0.001, paired t-test.
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Chemical Exchange Saturation Transfer Imaging of Glutamate
The gluCEST imaging was performed on a horizontal 11.7 T Bruker
scanner with a volume coil for radiofrequency transmission and a
quadrature surface coil for reception (Bruker, Ettlinger, Germany).
The ‘Mapshim’ routine was applied in a voxel encompassing the
slice of interest and a B1 map was also acquired to correct for
inhomogeneities of the saturation pulse. A gluCEST image
centered on the injection sites was acquired with a 2D fast spin-
echo sequence preceded by a frequency-selective continuous-
wave saturation pulse (300 × 300 μm2 in-plane resolution, 1 mm
slice thickness) with echo time/repetition time = 6/5,000 ms, 10
echoes and effective echo time = 30ms. The saturation pulse was
applied during 1 second with a 5-μT B1 amplitude. Two images
were acquired with saturation pulse applied either at +3 ppm
(Msat(+3 ppm), the center of CEST peak for Glu) or at a sym-
metrical frequency relative to bulk water (Msat(−3 ppm)).
The gluCEST contrast was calculated pixel by pixel, as a
percentage, by the equation: 100 × (Msat(−3 ppm)−Msat
(+3ppm))/Msat(−3 ppm).
High-Performance Liquid Chromatography Analysis
Six rats were killed with a lethal dose of pentobarbital 4 months
after lentiviral vector injection. Each striatum was rapidly dissected
out, weighted, and frozen in isopentane. Samples were stored at
− 80°C until HPLC analysis coupled with UV detection of N-Acetyl-
Aspartate (NAA) and N-Acetyl-Aspartyl-Glutamate (NAAG), accord-
ing to a protocol adapted from.11
ELISA Measurement of Human Ciliary Neurotrophic Factor
The striatum of five lenti-CNTF rats and four sham-operated rats
was rapidly dissected out on ice, homogenized in PBS with 1%
Triton X-100 and protease inhibitors (Roche, Basel, Switzerland).
After centrifugation (20,000 g, 15 minutes, 4°C), the supernatant
was collected and after fivefold dilution, analyzed by ELISA with
the Quantikine ELISA Human CNTF immunoassay kit in reference
to standards, according to the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA).12
Immunohistochemistry
Immunohistochemistry was performed on the brain of
paraformaldehyde-perfused rats as described previously,8 with
the following antibodies: ED1/CD68 (1:500; Serotec, Raleigh, NC,
USA), NeuN (1:2,000; Millipore, Billerica, MA, USA), and vimentin
(1:2,000; Calbiochem, La Jolla, CA).
Statistical Analysis
Results are expressed as mean± SEM. Paired t-tests were
performed with Statview. N indicates the number of animals. No
blinding was performed but rats were injected randomly with
lenti-CNTF in either the left or right striatum.
RESULTS
Lentiviral Vector-Mediated Expression of Ciliary Neurotrophic
Factor in the Rat Striatum
We first measured the levels of human CNTF by ELISA, 5 weeks
after infection with lenti-CNTF in the rat striatum. Ciliary
neurotrophic factor levels were 2.39 ± 0.53 ng/mg total protein
in lenti-CNTF injected rats, while it was below 3.10− 4 ng/mg total
protein in sham-operated rats.
To further evidence CNTF production in the rat striatum, we
performed immunostaining for vimentin, a marker of reactive
astrocytes known to be induced by CNTF.8,9 Astrocytes over-
expressed vimentin in a large part of the striatum injected with
lenti-CNTF (28.47 ± 4.80mm3, Figure 1A).
We also checked that lentiviral injection or transgene expres-
sion had no detrimental effect on striatal cells. There was no
detectable change in NeuN staining and no immunoreactivity for
ED1/CD68, a marker for activated microglia (Figure 1A), as already
reported.8,9
Ciliary Neurotrophic Factor Induces Multiple Changes in
Metabolite Concentrations
Rats injected with lenti-LacZ in one striatum and lenti-CNTF in the
contralateral striatum were imaged using a 7 T magnet, 1.5
to 3 months after infection. There was no detectable change in
T2-weighted signal in the striatum for any of the nine rats studied
(Figure 1B). Proton magnetic resonance spectroscopy was per-
formed on two voxels positioned over each striatum (Figure 1B).
High-quality spectra were acquired (Figure 1B), allowing the
reliable quantification of seven metabolites, using total creatine as
a reference.
There was a significant increase in the concentrations of two
metabolites enriched in glial cells: myo-inositol (Ins, +61± 7%,
Po0.001) and total choline (glycerophosphocholine+phosphocho-
line+choline, tCho, +33± 7%, Po0.001), in the CNTF striatum
compared with LacZ (Figure 1C). On the contrary, the astrocyte
metabolite glutamine (Gln) was decreased in the CNTF striatum
(−14± 3%, Po0.01). Surprisingly, CNTF also decreased the levels of
the neuronal metabolites NAA+NAAG (tNAA, − 19± 2%, Po0.001)
and glutamate (Glu, − 18± 2%, Po0.001, Figure 1C). Taurine (Tau)
concentrations were also significantly decreased by CNTF (−9± 1%,
Po0.001). The same pattern was observed independently of the
side of lenti-CNTF injection (Figure 1C), ruling out a possible bias
due to voxel position, chemical shift artifact, or intrinsic differences
between hemispheres. The same metabolic profile was observed in
three independent cohorts of rats.
The Decrease in N-Acetyl-Aspartate and N-Acetyl-Aspartyl
Glutamate Concentrations Is Confirmed by High-Performance
Liquid Chromatography Analysis
To measure NAA concentrations by an alternative method, we
performed HPLC analysis coupled with UV detection on striatal
samples. This method allows the separate measurement of NAAG,
which is otherwise combined with the main NAA peak on the
1H-MRS spectrum.
N-Acetyl-Aspartate levels were significantly decreased by
18± 3% in the CNTF striatum compared with the LacZ striatum
(Po0.01, Figure 2A), which is very similar to the difference
measured by 1H-MRS. There was also an important decrease in
NAAG levels with CNTF (−31 ± 3%, Po0.001, Figure 2A).
Chemical Exchange Saturation Transfer of Glutamate Imaging
Reveals a Decrease in Glutamate Levels that Matches the Volume
of Astrocyte Activation
To confirm the decrease in Glu levels with CNTF and to map its
spatial extension in vivo, we took advantage of the recently
developed NMR imaging technique called gluCEST.13 The gluCEST
contrast is correlated with Glu concentrations, allowing in vivo Glu
mapping with good spatial and temporal resolution.13 A lower
gluCEST contrast was observed in the CNTF striatum (Figure 2B).
The brain area displaying vimentin-positive reactive astro-
cytes matched precisely the zone exhibiting lower gluCEST
contrast (Figure 2B). To compare gluCEST with 1H-MRS
results, we calculated the average gluCEST contrast in the same
striatal voxels analyzed by 1H-MRS. A significant reduction in
gluCEST contrast was measured in the voxel positioned over
the CNTF striatum compared with the LacZ striatum (−14 ± 1%,
Po0.001, Figure 2C), which is consistent with 1H-MRS
measurements.
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DISCUSSION
Our study shows that CNTF triggers complex changes in striatal
metabolism, affecting metabolites enriched in astrocytes as well as
those enriched in neurons. The significant decrease in Gln levels
shows that CNTF does not globally increase the concentrations of
glial metabolites, but rather modulates the relative abundance of
specific brain metabolites. By alternating the side of lentiviral
vector injections, we ruled out possible bias due to spectroscopic
localization or lateralization. In addition, 1H-MRS results were
validated by two alternative methods. The decrease in NAA+NAAG
concentrations was confirmed ex vivo by HPLC analysis, providing
an independent measurement of these two metabolites. The
decrease in Glu levels was also observed by gluCEST imaging and
closely matched the volume displaying CNTF-activated astrocytes.
Ciliary neurotrophic factor is a neurotrophic cytokine with
demonstrated protective effects against multiple brain insults
including excitotoxicity1,12 and metabolic impairment.2,7 Ciliary
neurotrophic factor neuroprotective effects were reproduced in
nonhuman primates, opening the path to clinical trials for
amyotrophic lateral sclerosis,4 diseases of the retina5 and
Huntington’s disease.3 Therefore, it is rather unexpected that
CNTF reduces neuronal metabolite levels in the rat striatum.
Indeed, decreased tNAA levels are classically interpreted as
reflecting neuronal death or at least dysfunction in 1H-MRS
studies.14 However, using the same strategy to overexpress CNTF
in the rat striatum, we previously showed that CNTF does not alter
the expression of many neuronal proteins,8 does not modify the
spontaneous electrophysiologic activity of striatal neurons,15 and
confers significant neuroprotection against excitotoxicity.15 This
was consistent with two independent studies based on lentiviral
vectors,12,16 in which intrastriatalal CNTF levels were in the ng/mg
protein range, as measured in the present study. Other delivery
modes (adenoviral gene transfer2 and encapsulated cells releasing
CNTF17) confirmed the protective effects of CNTF against
striatal lesions. The levels of CNTF achieved with these different
strategies are not directly comparable to our ELISA measure-
ment. Encapsulated cells are known to produce CNTF less
efficiently due to their low survival rate after implantation.18 This
may explain the limited beneficial effects observed in a phase I
clinical trial for HD patients,3 although this strategy was
very efficient in primates.19 Considering the strong evidence for
CNTF neuroprotective effects in the striatum, our results show
that decreased tNAA and Glu levels may occur independently
of neuronal dysfunction, and may instead be associated with
significant neuroprotective effects.
Overall, CNTF induces a complex reorganization of striatal
metabolism. Accordingly, we previously showed that CNTF
activates the AMP kinase, a master regulator of energy
metabolism,7 and that CNTF alters the metabolic profile of
astrocytes.7 Given the importance of energy homeostasis for
proper neuronal function, it is tempting to speculate that such
metabolic plasticity may participate in CNTF neuroprotective
effects, as demonstrated in an in vitro model of metabolic
impairment.7
The molecular mechanisms mediating CNTF effects on neuronal
metabolites remain to be determined; they may be direct
or indirect. Indeed, both NAA and Glu metabolism involve
complex interactions between neurons, astrocytes but also
oligodendrocytes.20 The facts that (1) CNTF acts primarily on
astrocytes and (2) there is a strong spatial correlation between
reactive astrocytes and decreased Glu levels observed by gluCEST,
suggest that astrocytes may be involved in the remodeling of
striatal metabolism.
Figure 2. High-performance liquid chromatography (HPLC) analysis confirms decreased NAA and NAAG levels with ciliary neurotrophic factor
(CNTF) and chemical exchange saturation transfer of glutamate (gluCEST) imaging reveals lower Glu levels in the striatum displaying CNTF-
activated astrocytes. (A) Quantification of NAA and NAAG by HPLC coupled with UV detection on postmortem samples. Data are expressed as
nmol/mg of tissue (wet weight). N= 6; **Po0.01, ***Po0.001, paired t-test. (B) A representative gluCEST image exhibiting a lower gluCEST
contrast in the white matter, e.g., in the corpus callosum and anterior commissure, as described previously.13 GluCEST contrast is decreased in
the hemisphere injected with lenti-CNTF. The region with vimentin+ reactive astrocytes (black dots) closely matches the region exhibiting
lower gluCEST contrast. (C) Quantification of the average gluCEST contrast in voxels similar to the ones used for proton magnetic resonance
spectroscopy (1H-MRS). N= 4, ***Po0.001, paired t-test. Scale bar: 1 mm.
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Overall, we show that the neurotrophic cytokine CNTF induces
significant metabolic plasticity in brain cells. Such metabolic
signature would be classically interpreted as neuronal dysfunction
or death in 1H-MRS clinical studies. Instead, our results raise the
intriguing possibility that it may indicate ongoing compensatory
mechanisms.
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